New CFO, Pål Ryfors, joins Episurf to support commercial expansion and investor relations

Ryfors has vast experience from leading positions within the finance and banking sector both in the Nordics and internationally. Most recently, he was the CFO of Marginalen Bank, a Swedish bank employing some 350 people, where Ryfors was responsible for the strategic financial planning and management, as well as leading the financial operations and implementing corporate development initiatives. Previously, Ryfors was Head of Group Controlling at Hoist Finance. Prior to joining Hoist Finance, Ryfors was an investment banker at Societe Generale, where he joined after holding several leading positions in the restructuring of the Swedish operations of Kaupthing Bank.

‘’I am delighted to welcome Pål Ryfors to Episurf Medical as our new CFO. With Pål’s background and proven financial expertise, I am confident that Pål’s skill set will provide the requisite financial leadership to enable the organization to accelerate to the next level. His broad knowledge and experience is an excellent complement to the Episurf management team as we continue building our corporate infrastructure to meet our growth goals moving forward”, comments Rosemary Cunningham Thomas, CEO of Episurf Medical.

“I am very excited to join Episurf Medical at this interesting point in time. Clearly, the level of ambition is high and the scope of application for the company’s products and technology platform is both global and broad. This underlies the compelling commercial opportunity that lies ahead in the near future. I look forward to contributing to the company’s long term success as an innovator of intelligent, patient specific implant technology”, comments Pål Ryfors, CFO of Episurf Medical.

About Episurf Medical
Episurf Medical is endeavouring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.

Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.

         For more information, please contact:
         Rosemary Cunningham Thomas, CEO, Episurf Medical
         Tel: +46 (0) 70-7655892
         Tel: +44 (0) 7803-753603
         E-mail: rosemary@episurf.com